EHA 2021 | Managing toxicities associated with CAR-T therapies
Michael Wang
• 8 Jun 2021
Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, discusses the management of toxicities associated with chimeric antigen receptor T-cell (CAR-T) therapies. Prof. Wang outlines four main categories of CAR-T associated toxicities: cytokine release syndrome (CRS), neurotoxicities, infection-related toxicities and other toxicities including hypertension, hypoxia and hypophosphatemia. For CRS, Prof. Wang highlights the use of steroids. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
